2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3671 A Phase 1/2, first-in-human, multicenter study of DS3790, a CD37-directed DXd antibody–drug conjugate (ADC), in patients with B-cell non-Hodgkin lymphoma (B‑NHL)

Gilles Salles I, MD, PhD, Emmanuel Bachy I, MD, PhD2, Franck Morschhauser, phd3, Pier Luigi Zinzani, MD, PhD4, Masato Ishigami5, Jin Jin6, Girma Ayele7, Keiko Nakajima, MD, MSc8, Koji Izutsu, MD, PhD9
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France
3 Centre Hospitalier Régional Universitaire de Lille, Lille, France
4 IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant’Orsola, Bologna, Italy
5 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
6 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
7 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
8 Daiichi Sankyo, Inc., Basking Ridge, New Jersey, United States
9 National Cancer Center Hospital, Tokyo, Japan

Background and Significance: Novel efficacious and tolerable treatment options are needed for patients with relapsed/refractory B-NHL. The transmembrane protein CD37 is widely expressed across B-cell lymphomas and thus is a promising therapeutic target. DS3790 is an ADC comprising an anti-CD37 antibody and a DXd payload (potent topoisomerase I inhibitor) connected by a tetrapeptide-based enzymatically cleavable linker. The linker–payload system is a component of other ADCs approved to treat solid tumors.

Study Design and Methods: DS3790-076 (NCT07220616), is a phase 1/2, first-in-human, open-label, multicenter, global study of DS3790, currently enrolling patients with B-NHL (total N≈400). Patients must be adults with an Eastern Cooperative Oncology Group performance status of 0, 1, or 2; have histologically documented B-NHL per the World Health Organization Classification of Haematolymphoid Tumours, 5th Edition; and have provided informed consent.

DS3790-076 comprises monotherapy (dose escalation to determine the recommended phase 2 dose and dose expansion/optimization), combination therapy (dose escalation and randomization/optimization), and a phase 2 part. Monotherapy dose expansion/optimization comprises treatment arms randomized to receive 1 of 2 doses of DS3790. Each combination-therapy part has 2 cohorts (A and B). In combination dose escalation, Cohort A receives DS3790 at 1 of 2 doses in combination with partner regimen A, and Cohort B receives DS3790 at 1 of 2 doses in combination with partner regimen B. In combination randomization/optimization, Cohort A is randomized to DS3790 at 1 of 2 doses plus partner regimen A; Cohort B is randomized to DS3790 at 1 of 2 doses plus partner regimen B.

The primary objective for phase 1 is to assess safety/tolerability of the monotherapy or combination therapy treatment regimen. The primary objectives for phase 2 are to assess safety/tolerability and efficacy.

Secondary endpoints include complete response (CR), objective response, disease control, duration of CR, duration of response, time to response, progression-free survival, overall survival, pharmacokinetics, and immunogenicity. CR rate and its confidence intervals will be calculated using the Clopper–Pearson method. CR rate differences will be calculated using the Miettinen–Nurminen method. Enrollment is ongoing.

Gilles Salles I, MD, PhD: Ipsen - Research Funding; Daiichy Sankyo - Research Funding; Lyell - Research Funding; Janssen - Research Funding; Abbvie - Research Funding; Genentech/Roche - Research Funding; Genmab - Research Funding; Abbvie - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Lilly - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Daiichy Sankyo - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony)